Article

PDF
Access to the PDF text
Advertising



Archives of cardiovascular diseases
Volume 111, n° 5
pages 349-356 (mai 2018)
Doi : 10.1016/j.acvd.2017.07.005
Received : 4 May 2017 ;  accepted : 29 July 2017
Clinical research

Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study
Apixaban en prévention des accidents vasculaires cérébraux et des embolies systémiques chez les patients en fibrillation atriale non valvulaire en France : rationnel et design de l’étude PAROS
 

Figure 1




Figure 1 : 

Schematic representation of the study enrolment process. AC: anticoagulant; AF: atrial fibrillation; HCP: healthcare practitioner; NVAF: non-valvular AF.

EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline